The effect of dopamine agonist therapy on dopamine transporter imaging in Parkinson's disease
โ Scribed by J. Eric Ahlskog; Ryan J. Uitti; Michael K. O'Connor; Demetrius M. Maraganore; Joseph Y. Matsumoto; Kathy F. Stark; Margaret F. Turk; Omer L. Burnett
- Publisher
- John Wiley and Sons
- Year
- 1999
- Tongue
- English
- Weight
- 87 KB
- Volume
- 14
- Category
- Article
- ISSN
- 0885-3185
No coin nor oath required. For personal study only.
๐ SIMILAR VOLUMES
Dopamine D1-like and D2-like receptors on peripheral blood lymphocytes (PBL) were assayed in 50 de novo patients with idiopathic Parkinson's disease (PD), in 36 neurologic control subjects (multiple-system atrophy, n โซืกโฌ 16; essential tremor, n โซืกโฌ 10; other neurodegenerative diseases, n โซืกโฌ 10), an
Increasing evidence suggests that the dopamine transporter is situated almost exclusively on dopamine neurons. Accordingly, it is an valuable marker for Parkinson's disease and other pathological states of dopamine neurons. We previously demonstrated that the potent dopamine transport inhibitor [ 12